TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03962270

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: shock wave device
Description: The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock wave device
Description: The experimental group (group ESWT) guided by ultrasound: conventional rehabilitation training is given priority to with strength training, application of pain when necessary, under the guidance of ultrasound ESWT treatment control group (routine rehabilitation group) : conventional rehabilitation training is given priority to with strength training, oral pain when necessary, under the guidance of ultrasound ESWT treatment (shock energy flow density of 0)
Study: NCT01198119

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Location of the suspected lesions
Description: The suspected lesions will be located before the excision, during the surgery.~1. With traditional light~2. NBI technique The images will be recorded and compared

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: In case of suspected lesions detected by the NBI technique, this area is biopsied

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lesion excision/Surgery
Description: In case of positive biopsy, the suspected lesions is excised
Study: NCT03803085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: Participants in the control group only saw their own daily walking steps using the WeChat. They did not use WeChat to see other group members' daily steps and did not contact other group members. The participants were asked to use the app every day. A message (through WeChat) was sent to remind them to use the application if they had not done so within three days.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment condition
Description: Participants in the experimental condition used WeChat for 4 weeks to see their own and other's walking steps and also were able to contact other group members. The participants were asked to use the application every day. A message (through the group chat) was sent to remind them to use the application if they have not done so within three days.
Study: NCT01614613

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bayer G3 / Tatsu System
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Freestyle Lite® Meter and Test Strips with ZipwikTM tabs
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips
Description: Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One Touch® VerioTM Pro/One Touch® VerioTM Test Strips
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Truetrack® Meter/Truetrack® Test Strips
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study: NCT01725074

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case Management CM CHD
Description: Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:~* Biweekly/monthly telephone consultations or home visits~* Identification of health or personal problems of the patient~* Monitoring of medical parameters~* Coordination of contact with health care providers if necessary~* Support to the patient related to health status and environmental changes~* Promote disease-self management through coaching~* Counseling, that is focused on emotional support and active listening

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Interaction
Description: Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
Study: NCT02857374

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diagnostic Microscopy
Description: Undergo intravital microscopy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorescein Sodium Injection
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Lymph Node Biopsy
Description: Undergo standard of care sentinel node biopsy
Study: NCT04582097

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: angiotensin-converting enzyme inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: same odor, color and size as the drug but without the active ingredient
Study: NCT02100566

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (Care giver burden focus)
Description: An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling (patient autonomy focus)
Description: An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
Study: NCT04133480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GWP42003-P
Description: oral solution of 100 milligrams per milliliter (mg/mL) cannabidiol (CBD)
Study: NCT03148288

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: VItamin D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT01026688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit
Description: Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
Study: NCT04583488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraperitoneal docetaxel
Description: Up to 3 dose levels of intraperitoneal docetaxel will be studied (25mg/m2, 35 mg/m2, 45 mg/m2).
Study: NCT03182920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT04607603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol Oral Product
Description: Cannabidiol is administered in capsules. Each capsule contains 200mg of CBD administered 3 times daily to a total of 600mg per die

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered in capsules of identical appearance to CBD capsules in 3 doses per die
Study: NCT03665571

Intervention type: DIAGNOSTIC_TEST
Intervention: Receptor specific activation method
Description: NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4

Intervention type: DIAGNOSTIC_TEST
Intervention: Receptor specific activation method
Description: NK cell was incubated with P815-ULBP1+CD48 cells that trigger NK cell synergy via NKG2D and 2B4
Study: NCT03594877

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sublimated mare milk
Description: The dietary supplement mare milk product, which is obtained from fresh (few hours) through sublimation process. This product is first mixed with warm water (37-38 degrees of Celsius) and then will be given to participants.
Study: NCT01482871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study: NCT03197805

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PAM 50 test
Description: Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio \<2 and 4 ≤HER2 gene number copy \< 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
Study: NCT00095199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 400/250 mg/m\^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel 75 mg/m\^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
Study: NCT01999387

Intervention type: DIETARY_SUPPLEMENT
Intervention: Allergenic food
Study: NCT02587156

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal serving at high dietary protein
Description: Participants are habituated to a high level of dietary protein intake for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal serving at low dietary protein
Description: Participants are habituated to a low level of dietary protein intake for 21 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Meal serving
Description: To investigate impact of habituated protein level

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Meal serving
Description: To investigate impact of habituated protein level
Study: NCT00512187

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low calorie diet
Description: Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
Study: NCT04133571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% Lidocaine
Description: 0.05% lidocaine with normal saline as a bladder irrigation solution after transurethral surgery intravenous pethidine to decrease CRBD if needed
Study: NCT03287479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gavi® Vitrification
Description: A closed, semi-automated vitrification system

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cryotop® Vitrification
Description: An open, manual vitrification system
Study: NCT02100852

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGR-1202 + Obinutuzumab + Chlorambucil
Description: TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
Study: NCT00595660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine Needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine Needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine Needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine Needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine needle aspiration
Study: NCT04506970

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Doppler Ultrasound of the Placenta
Description: Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.

Intervention type: DIAGNOSTIC_TEST
Intervention: Comprehensive Doppler Ultrasound of the Placenta
Description: Ultrasound measures to be collected include uterine artery (UtA) and umbilical artery (UA), systolic/diastolic (S/D) ratio, resistance index (RI), pulsatility index (PI) and presence of early diastolic notch.

Intervention type: OTHER
Intervention: Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)
Description: In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.

Intervention type: OTHER
Intervention: Verasonics Ultrasound scanner (ultra-sensitive Doppler imaging)
Description: In addition, a Verasonics ultrasound scanner will be used for ultra-sensitive Doppler imaging. Data will be collected on vessel density, periphery-to-center vessel density ratio (VDR) and microvessel morphology.
Study: NCT03870763

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon Beta-1a
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.
Study: NCT00116805

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TDF
Description: 300 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADV
Description: 10 mg tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TDF placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADV placebo
Description: Tablet administered orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: 200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
Study: NCT01479660

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
Study: NCT02977624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cognitive Orientation to daily Occupational Performance
Study: NCT03711981

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Study: NCT00595660

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine needle aspiration

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FNA - fine needle aspiration
Description: Fine needle aspiration
Study: NCT00869232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Velcade
Description: 1.0mg/m2 days 1, 5, 8, \& 11
Study: NCT01482871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALG-1001
Description: 5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
Study: NCT00869232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 10 mg/m2 day 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 200 mg days 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg day 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 10 mg/m2 day 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin
Description: 10 mg/m2 day 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 400 mg/m2 day 5-8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 40 mg/m2 day 5-8
Study: NCT02244944

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EZ-Urso combination therapy
Description: Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
Study: NCT03405870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoflipid
Description: Administration of lipid injectable emulsion
Study: NCT01509573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Strengthening Intervention in Rwanda (FSI-R)
Description: Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.~8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material.
Study: NCT02156674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naglazyme®
Description: 1 mg per kg of body weight administered once weekly as an intravenous infusion
Study: NCT01192906

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral doses, once a day for 52 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 1, once a day for 52 weeks
Study: NCT01491490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GWP42003 : GWP42004 (40:1)
Description: Capsules taken once a day for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules taken once a day for 6 weeks
Study: NCT01192906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bitopertin [RO4917838]
Description: Oral dose level 2, once a day for 52 weeks
Study: NCT01281358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HOP-ON
Description: A programme of activities which promote motor development

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SMILES
Description: Details are provided on ways for parents to interact with their premature infants
Study: NCT00352365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given orally